Tamoxifen for prevention of breast cancer: Extended long-term follow-up of the IBIS-I breast cancer prevention trial. The Lancet Oncology, Jan. 2015, Vol. 16(1), p.67-75.
Cuzick, J., et al.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71171-4/fulltext?rss=yes
Four previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast cancer in healthy women at increased risk of breast cancer in the first 10 years of follow-up. We report the long-term follow-up of the IBIS-I trial, in which the participants and investigators remain largely masked to treatment allocation.
